Please contact the National Centre for Asbestos Related Diseases (NCARD) directly for information on the below.
Phase I study of Cisplatin, Pemetrexed, plus CP-870,893 as first line treatment of malignant pleural mesothelioma.
This clinical trial is adding an immunotherapy to standard chemotherapy for people who have not had previous chemotherapy treatment for malignant pleural mesothelioma. The trial is available at Sir Charles Gairdner Hospital. Principal Investigstor: Prof Anna Nowak
Phase I study of Cyclophosphamide in combination with pemetrexed based chemotherapy to deplete regulatory T cells.
This clinical trial is adding a tablet immunotherapy, cyclophosphamide, in order to reduce the number of inhibitory immune cells in the blood of people with mesothelioma or lung cancer and enhance the anti-tumor immune response. The trial is available at Sir Charles Gairdner Hospital. Principal Investigator: Prof Anna Nowak.
B2P2M2 study: a multicentre phase II study of BNC105P as second line therapy for malignant pleural mesothelioma.
This clinical trial is examining the use of a blood vessel targeting drug, BNC105P, to treat people with mesothelioma who have previously received one line of chemotherapy. The trial is available at several centers around Australia and is run through the Australian Lung Cancer Trials Group. Principal Investigator: Prof Anna Nowak.
F-MISO PET scanning in Mesothelioma.
This clinical research is looking at the use of a newer type of PET tracer, F-Misonidazole, and its use in detecting areas of low oxygen concentration in mesothelioma. Low oxygen concentration in tumors may predict for poor response to chemotherapy or radiotherapy. The trial is available at Sir Charles Gairdner Hospital. Principal Investigator: A/Prof Roslyn Francis.